Analysis of the Human Protein Atlas allowed to pinpoint CCR9 as a potential immunotherapeutic target for T-ALL [138], and analysis of GENT2 allowed to determine the specificity of CCR9 expression in normal and tumor tissue samples [83]. Here, CCR9 is linked to acute lymphoblastic leukemia.